{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:49:34Z","timestamp":1787168974154,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.516211","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T01:42:50Z","timestamp":1601602970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China"],"prefix":"10.3389","volume":"11","author":[{"given":"Zunwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"9","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jns.2009.03.020","article-title":"MuSK-antibody-positive myasthenia gravis in a South Asian population","volume":"284","author":"Chang","year":"2009","journal-title":"J Neurol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jocn.2005.04.028","article-title":"MuSK antibody-positive, seronegative myasthenia gravis in Korea","volume":"13","author":"Lee","year":"2006","journal-title":"J Clin Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0929-6646(08)60171-0","article-title":"Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan","volume":"107","author":"Huang","year":"2008","journal-title":"J Formos Med Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.autrev.2013.03.005","article-title":"Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis","volume":"12","author":"Mori","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-005-0032-8","article-title":"MuSK-antibody positive pure ocular myasthenia gravis","volume":"253","author":"Hanisch","year":"2006","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneur.62.6.1002","article-title":"Anti-MuSK myasthenia gravis presenting with purely ocular findings","volume":"62","author":"Caress","year":"2005","journal-title":"Arch Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2169\/internalmedicine.51.8196","article-title":"An ocular form of myasthenia gravis with a high titer of anti-MuSK antibodies during a long-term follow-up","volume":"51","author":"Hosaka","year":"2012","journal-title":"Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mus.23847","article-title":"Pure ocular anti-musk myasthenia under no immunosuppressive treatment","volume":"48","author":"Zouvelou","year":"2013","journal-title":"Muscle Nerve."},{"key":"B16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/bjo.2006.108498","article-title":"Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-2005-858629","article-title":"[Ocular involvement in MuSK antibody-positive myasthenia gravis]","volume":"223","author":"Bau","year":"2006","journal-title":"Klin Monbl Augenheilkd."},{"key":"B18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10072-019-04038-4","article-title":"Anti-MuSK ocular myasthenia with extrinsic ocular muscle atrophy: a new clinical phenotype?","volume":"41","author":"Ricciardi","year":"2020","journal-title":"Neurol Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"2","author":"Illa","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B21","first-page":"137","article-title":"Neuroimmunology","author":"Xianhao","year":"1993"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns","volume":"116","author":"Stickler","year":"2005","journal-title":"Clin Neurophysiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1196\/annals.1405.005","article-title":"Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis","volume":"1132","author":"Wolfe","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ana.410370513","article-title":"Acetylcholine release in myasthenia gravis: regulation at single end-plate level","volume":"37","author":"Plomp","year":"1995","journal-title":"Ann Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mus.21642","article-title":"Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia","volume":"42","author":"Niks","year":"2010","journal-title":"Muscle Nerve."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/mus.880161109","article-title":"Neuromuscular transmission in amyotrophic lateral sclerosis","volume":"16","author":"Maselli","year":"1993","journal-title":"Muscle Nerve."},{"key":"B29","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia gravis and associated diseases","volume":"6","author":"Tanovska","year":"2018","journal-title":"Open Access Maced J Med Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity."},{"key":"B31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2249.1995.tb03674.x","article-title":"Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease","volume":"100","author":"Mappouras","year":"1995","journal-title":"Clin Exp Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-0404.1995.tb00432.x","article-title":"Associated autoimmune diseases in myasthenia gravis. A population-based study","volume":"91","author":"Christensen","year":"1995","journal-title":"Acta Neurol Scand."},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J Neurol Sci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.516211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T01:42:51Z","timestamp":1601602971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.516211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":33,"alternative-id":["10.3389\/fneur.2020.516211"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.516211","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"article-number":"516211"}}